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ABSTRACT 
Pharmaceuticals specific molecularly imprinted polymers nanoparticles (MIPNPs) were 
synthesized and applied onto the polyvinylidene fluoride (PVDF) membranes previously subjected 
to the plasma treatment. Diclofenac-, metoprolol- and vancomycin-MIPs were applied onto the 
membranes and scanning electron microscopy was employed to visualize MIPNPs on the 
membrane. After functionalization of the membranes with target-specific MIPs the molecularly 
imprinted membranes (MIMs) affinity against their targets was evaluated using solid phase 
extraction (SPE) technique coupled with high performance liquid chromatography (HPLC). MIMs 
were used as filters to load the target solutions through employing a vacuum pump to evaluate the 
amount of pharmaceuticals in filtrate. Moreover, a comparative study was performed by 
comparing the efficiency of MIMs functionalized either by adsorption or covalent immobilization. 
The capacity analysis of MIPNPs by SPE-HPLC revealed 100%, 96.3%, and 50.1% uptake of 
loaded solution of metoprolol, diclofenac and vancomycin, respectively. MIMs showed 99.6% 
uptake with a capacity of 60.39 ng cm2 for metoprolol; 94.7% uptake with a capacity of 45.09 ng 
cm2 for diclofenac; and 42.6% uptake with a capacity of 16.9 ng cm2 for vancomycin. HPLC 
detection limits of targets were found as 3.7, 7.5 and 15 ng mL-1 for diclofenac, metoprolol and 
vancomycin respectively. A small scale pilot test was also conducted which indicates the 
promising future applications of the developed MIMs for high volume of filtrates especially in the 
case of the plasma-treated PVDF membranes prepared by covalent immobilization of the MIPs.  
 
Keywords: Polyvinylidene fluoride (PVDF) membranes, Molecularly imprinted polymers 
nanoparticles (MIPNPs), Plasma treatment, Water purification, Pharmaceuticals.  
3 
 
1. Introduction 
Pharmaceuticals are active compounds with biological effects and they are used in many 
applications for human and veterinary medicine. However, part of the administered dose is 
excreted as the active substance and/or as metabolite, essentially through the organisms’ urine 
system and the biliary system leading to a release of drugs in the environment [1-3]. This problem 
has been recognized in the US in the 1970s, and around ten years later in England. To date, the 
continuous advances in analytical techniques have raised concern about the levels of these 
compounds in wastewater. Sewage treatment is not efficient enough to eliminate most of these 
compounds which remain in the effluents and then get into the surface and groundwater. So far 
antibiotics, beta-blockers, antiphlogistics, vasodilatators, antiepileptics, sympathomometics, lipid 
regulators and anti-epileptics have been found in manure, sewage, wastewater, groundwater and 
drinking water [4,5]. 
Concentrations up to mg L-1 have been detected in effluents for single substances in Asian 
countries [6]. Pharmacodynamic and pharmacokinetic studies are largely carried out during the 
drug development process and environmental risk is also assessed. However, a risk assessment 
needs to be developed as well as assessment procedures within a case-by-case approach [6-7]. 
With the presence of trace level of pharmaceutical in drinking water supplies, the issue has become 
a public health concern. Further studies pointed out the adverse effects including endocrine 
disruption, genotoxicity, resistance in pathogenic bacteria and aquatic toxicity, nevertheless 
chronic health effects are not well known yet [8]. Constant development of analytical techniques 
is continuously improving pharmaceuticals detection in the aquatic environment and nowadays 
detections of residues at the amount of nanogram per litre are possible [9]. One of the main causes 
for the dispersion of pharmaceuticals after human treatment is the lack of efficiency of sewage 
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treatment plants (STPs) in their mineralization, with evidences of the occurrence of more than 160 
different pharmaceuticals in STP effluent, groundwater and surface water [6, 10]. In wastewater 
treatment, two elimination procedures are important, biodegradation which occurs in the aerobic 
treatment and adsorption to suspended solids. If not removed in the waste water treatment plants 
(WWTPs), the drugs will spread into the ecosystem. Most WWTPs employ activated sludge 
operation in which microorganisms are used to mineralize the compounds to carbon dioxide and 
water, or reduce the pollutant to an acceptable structure. Another way to remove the substances is 
by stripping into air or by sorption onto sludge. Moreover, some residues may be subject to 
phototransformation. To summarize, the five mechanisms to remove pharmaceutical substances 
include phototransformation, sorption, air stripping, uptake by plants and biotransformation [9, 
11]. 
Since many years, researchers have been trying to develop membranes to detect or extract 
pharmaceuticals from water. Membrane filtration has been exploited to optimize the removal of 
pollutants such as pesticides and pharmaceuticals. In wastewaters treatment plants, membrane 
bioreactor (MBR) appears to be an interesting advanced technology. In fact, MBR encompasses 
organic matter degradation with membrane filtration more efficient than the conventional activated 
sludge (CAS) process with 56% elimination of diclofenac residues for MBR versus 26% for the 
CAS. MBR can be equipped with hollow-fibre ultrafiltration membranes, microfiltration-
membrane or flat-sheet membrane [12]. Others studies characterized the removal of uncharged 
trace organics by nanofiltration (NF) membranes due to steric hindrance, whereas polar trace 
organics removal was influenced by electrostatic interaction with the charged membrane. Several 
studies compared the removal of pharmaceuticals with different kind of membrane systems. 
Reverse osmosis (RO) membranes with a molecular weight cut-off inferior to 200 Daltons 
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provided a good removal with more than 90% removal of the tested compounds; largely more 
efficient than NF membranes. These significant results suggest that MBR-RO would provide 
efficient removal of the tested micropollutants [13]. 
Martínez and colleagues coupled membrane separation and photocatalytic oxidation 
processes for the degradation of pharmaceuticals [14]. They explored nanofiltration and reverse 
osmosis method and concluded that nanofiltration exhibits better conditions, in terms of power 
operation and time saving. They also suggested that the combination of photocatalytic oxidation 
with membrane separation would be a feasible alternative for pharmaceutical removal for 
wastewaters [14]. However, the occurrence of pharmaceuticals in environment and drinking water 
are still high in both developed and undeveloped countries. This emphasizes the lack of efficiency 
of WWTP and explains the large number of studies focusing on membrane development. 
Nanomaterials such as graphene and carbon nanotubes have also been used to develop efficient 
filtration systems for water purification due to their superior characteristics [15-19].  
With the lack of efficiency of pharmaceuticals removal in water, researchers focused on 
improving the selectivity of membranes for toxins and drugs [20-22]. Therefore, the incorporation 
of selective ligands to the PVDF membrane for the selective removal of pharmaceuticals has been 
investigated in this work for the first time. Three commonly used drugs including diclofenac as a 
pain killer, metoprolol as a β-blocker and vancomycin as an antibiotic were selected. Molecular 
imprints of these molecules were created in the form of nanoparticles using a novel solid phase 
synthesis method [23-25]. After obtaining MIPs nanoparticles (MIPNPs) with high quality and 
uniform size, the capacity analysis was conducted by employing solid phase extraction (SPE) 
technique coupled with HPLC. The PVDF membranes were processed with plasma treatment for 
surface modification to add functional groups to the membranes prior to incorporating high 
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capacity and affinity MIPs both by adsorption and covalent immobilization. The results provide a 
new and promising technology for the purification of water sources from pharmaceutical products 
by using nanostructured molecularly imprinted membranes (MIM).  Scheme 1 illustrates the entire 
work with major steps. 
addition of 
carboxylic groups
1. PVDF membranes
2. Plasma treatment on 
the membranes
3. Functionalization of 
nanostructured polymeric 
membranes with MIPNPs 
4. Water purification of 
pharmaceuticals using target 
specific membranes 
5. Filtrate analysis with 
HPLC
 
Scheme 1. Development of functionalized nanostructured polymeric membranes for water 
purification of pharmaceuticals using target specific membranes. 
2. Experimental section 
2.1. Reagents and chemicals  
Metoprolol, diclofenac, vancomycin hydrochloride, ethanol, 60 mL SPE tubes and 20 
μm pore frits, acetonitrile (ACN), acrylic acid and sodium dihydrogen phosphate monohydrate 
were all obtained from Sigma-Aldrich (Poole, UK). 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) and N-hydroxysuccinimide (NHS) were obtained from Fisher Scientific 
(Loughborough, UK). Glass beads (Spheriglass® 2429, 53 μm < diameter < 106 μm) were from 
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Blagden Chemicals (UK). Nitrogen gas was obtained from BOC gases (Manchester, UK). All 
chemicals and solvents were analytical or HPLC grade with more than 95% purity and were used 
without further purification.  
2.2. Apparatus and equipment 
A Sartorius (Göttingen, Germany) analytical balance was used to weigh compounds and 
membranes. For MIPs and buffers productions a KNF LABOPORT® (KNF Neuberger, Inc., USA) 
pump was used to apply a vacuum atmosphere. The polymerization of the MIPs has been carried 
out thanks to a Philips Facial tinner HB175 (Philips, UK) UV source. After the production, MIPs 
were analyzed by DLS Zetasizer Nano (Nano-S) from Malvern Instruments Ltd (Malvern, UK) 
and the absorbance was determined using Shimadzu UV-2100 (Shimadzu, Japan). After SPE 
analysis, samples were analyzed using an Agilent 1200 Series Rapid Resolution System with a 
reverse phase C18 phenomenex column (Torrance, California, U.S.). For the dissolution of 
compounds and break down of MIP agglomerates Hilsonic sonicator (Hilsonic, UK) and vortex 
genie 2 (Scientific instruments, Inc., USA) were employed.  
2.3. MIP synthesis 
A novel solid phase production technique was used to synthesize the MIPs by 
immobilizing the templates on micro glass beads. The detail procedures for the preparation of 
derivatized glass beads and immobilization of the template on the solid support were previously 
reported [2326]. After the preparation of the template immobilized beads, MIPs were produced as 
nanoparticles by employing a three-step production method [23, 26]. Briefly, the polymerization 
mixture immersed the bulk of micro glass beads, and the polymerization was then performed at 
room temperature under UV source during 2 minutes (step 1). The temperature was then adjusted 
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to 0 °C to discard low affinity particles using 50 mL ACN (step 2). Finally, the high affinity MIPs 
were eluted from the affinity media by passing three fractions of 50 mL of ACN at 60 °C (step 3). 
The characterization of the MIPs size and quality were determined by employing DLS and 
transmission electron microscopy technique [30]. The size of diclofenac-, metoprolol- and 
vancomycin-MIPNPs were found to be 132.3 ± 3.2 nm, 169.4 ± 3.5 nm and 263 ± 10 nm, 
respectively.  
2.4. Capacity analysis of MIPs by solid phase extraction-HPLC 
  SPE-HPLC was carried out to evaluate the MIPs capacity by loading pharmaceuticals 
onto the MIPNPs and measuring the remaining pharmaceuticals concentration by reverse phase 
HPLC. SPE columns were set up in duplicate for each pharmaceutical. First EDC-NHS chemistry 
was used to bind the MIPNPs (containing primary amino groups) to glass beads (containing 
carboxylic groups). MIPNPs solutions (9 mL) were mixed with 1mL of EDC-NHS (0.4 M-0.1 M) 
prior to be poured onto 1 g of derivatized glass beads and incubated for 2 hours at room 
temperature. The mixture was then transferred into the empty SPE columns. Glass beads were 
retained into the column by two pore frits before processing 8 washing steps with double distilled 
water using a vacuum system. Samples of 200 ng mL-1 of each pharmaceutical were prepared and 
loaded (1 mL) throughout the columns. The eluted samples were collected in glass vials prior to 
HPLC analysis. Buffer (water) was loaded (1 mL) after the pharmaceutical in order to determine 
a possible release of the analytes. Finally washing steps with 1 mL of cold (25°C) and hot 
acetonitrile (60°C) were carried out to evaluate drugs removal. For the HPLC analysis an Agilent 
1200 Series Rapid Resolution System was employed. The column used was a reverse-phase C18 
Gemini phenomenex column (150 x 4.6 mm with 5 µm particles). The mobile phase was applied 
in a gradient mode for vancomycin and metoprolol starting with acetonitrile (ACN) and sodium 
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dihydrogen phosphate monohydrate (25 mM, pH 3.4) within the HPLC instrument and eluted with 
a 1 mL min-1 flow rate before being submitted to analyse at 210 nm. ACN and the buffer were 
mixed over 10 minutes with a gradual increase of ACN from 10% to 35%. For diclofenac, an 
isocratic mode was employed using 70% ACN and 30% buffer after optimization studies. Each 
sample was analyzed in triplicate at 25 oC. 
2.5. Plasma treatment on membranes 
An atmospheric pressure plasma method based on dielectric barrier discharge (DBD) 
technology was employed for functionalization of PVDF microfiltration membranes with 
carboxylic groups. The DBD plasma reactor consists of 2 parallel electrodes one of which is 
covered with a 3 mm thick insulating glass plate and connected to a high voltage power supply 
(Fig.1). In order to guarantee homogeneous plasma treatment, the top electrode moves back and 
forth in 10 passes over the grounded bottom electrode at a speed of 2 m/min. The gap between the 
electrodes was limited to 2 mm to ensure stable plasma operation. Plasma discharges were 
generated at a fixed frequency of 1.5 kHz and a dissipated power of 0.1 W/cm2 of electrode surface. 
Argon was used as carrier gas. Acrylic acid was nebulized during the plasma treatment with an 
atomizer (TSI model 3076) to produce a fine aerosol. Droplet sizes were measured with a particle 
size analyzer (TSI model 3080) and were found in the range of 10-300 nm with a maximum 
concentration around 50 nm. The small particle size generated by this atomizer ensures optimum 
reaction conditions in the plasma. Immediately after plasma treatment, the water contact angle of 
the functionalized membranes and the time needed for a water drop to penetrate into the membrane 
were determined with a drop shape analyser (Krüss DSA100). Prior to MIPNPs application, 
plasma-treated membranes were cut in small pieces (2.4 x 7 cm, area= 16.8 cm2) and their weight 
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assessed using analytical balance. MIPNP immobilized and standard membranes were also 
characterized by employing scanning electron microscopy (Philips XL30 ESEM). 
2.6. Molecular imprinted membrane (MIM) characterization 
The membranes properties were evaluated by measuring their capacity to absorb the 
drugs from aqueous solution during a fast filtration. Before use, the membranes were subjected to 
a washing application and a drying process at 80°C. Two membranes coated with MIPNPs were 
used per assay to filter 4 mL of solution. A vacuum pump with a pressure level of 0.5 bar and the 
frequency of 50Hz (230V, 0.6A, 100W) was employed for the filtration. Membranes were initially 
washed with double distilled water prior to be fitted on the filtration system as recommended by 
GVS Filter Technology. A small aliquot (4 mL of 200 ng mL-1 of each drug) was loaded onto the 
membrane and filtration was executed with a vacuum system. Filtrates were collected in glass vials 
prior to HPLC analysis. 
2.7. Comparative study for MIP immobilization on membrane 
MIPNPs were immobilized on one set of membranes by adsorption without EDC-NHS 
chemistry. Another set of membranes was subjected to an EDC (0.2 M)-NHS (0.05 M) solution 
for 30 minutes before MIPNP application. The principle of this application relies on a common 
method which activates carboxyl groups on the surface of the membranes and allows the 
immobilization of MIPNPs via their amino groups [23]. All membranes were then dried for one 
hour in an oven at 80ºC. The membranes were used in a filtration system to filter the solutions of 
targets (200 ng mL-1 diclofenac on diclofenac-MIP immobilized membrane, 200 ng mL-1 
metoprolol on metoprolol-MIP immobilized membrane, 200 ng mL-1 vancomycin on vancomycin-
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MIP immobilized membrane). For control experiment, 200 ng mL-1 diclofenac was filtered 
through MIP-free membranes. 
 
Fig 1. Picture and schematic drawing of the atmospheric plasma set-up. 
3. Results and discussions  
3.1. Diclofenac MIPs capacity analysis by SPE-HPLC 
MIPNPs specific for diclofenac, metoprolol and vancomycin were prepared as already 
explained elsewhere [30]. After characterization, the MIPNPs were attached to a solid support 
(glass beads) [26-28], packed in empty SPE columns and their capacity was assessed by SPE-
HPLC. To detect diclofenac in samples, an HPLC detection method was developed and a detection 
limit of 3.7 ng mL-1 was obtained. The investigation range of 1.5-1000 ng mL-1 allowed linear 
regression analysis to be carried out with average data of three analysis and R2 value was found as 
0.9995 with very low standard deviation (<0.07%). Diclofenac (200 ng mL-1) was then loaded (1 
mL) onto the MIPNPs columns; the filtrates were collected and the residual amount of diclofenac 
was determined by HPLC (Table 1, Fig.2a). Four diclofenac standards were also analyzed with 
the real samples to calculate the response and to do comparative data analysis. The graph shows 
that the HPLC responses after drug loading on SPE were relatively low with an average 
concentration of 27.1 ng mL-1 which indicated high level of uptake of diclofenac by diclofenac 
MIPNPs with an average uptake of 96.3%. Buffer, cold acetonitrile (ACN) and hot ACN were also 
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loaded on SPE columns after diclofenac and these solutions were also analyzed by HPLC to 
determine the affinity between diclofenac MIPNP and its target. Diclofenac was not removed 
significantly from the SPE column either by buffer or ACN. The HPLC response was found very 
little for buffer loading, whereas it was zero level for both cold and hot ACN (Fig.2a).    
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Fig 2. Diclofenac (a), metoprolol (b) and vancomycin (c) concentrations determined by HPLC in 
standards and before and after SPE application. Loading sample represents the starting solution of 
each pharmaceutical. 
a) 
b) 
c) 
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Table 1: Pharmaceutical detection by HPLC after SPE analysis. 
SPE Application 
SPE loading 
1 
SPE* loading 
2 
Buffer 
loading 1 
Buffer* 
Loading 2 
Cold ACN 
loading 25°C 
Hot ACN 
loading 60 
°C 
D
ic
lo
fe
n
a
c 
Residual 
concentration in 
filtrates ng mL-1 
17.33 36.89 10.46 7.29 0 0 
Capacity percentage 97.6% uptake 94.9% uptake 5.3% release 1.45% release 0% release 0% release 
M
et
o
p
ro
lo
l 
Residual 
concentration in 
filtrates ng mL-1 
0 0 0 0 0 0 
Capacity Percentage 100% uptake 100% uptake 0% release 0% release 0% release 0% release 
V
a
n
co
m
y
ci
n
 
Residual 
concentration in 
filtrates ng mL-1 
100.68 63.83 20.07 33.66 0 0 
Capacity percentage 38.9% uptake 61.3% uptake 12.2% release 20.4% release 0% release 0% release 
*The experiments were performed on two columns used in parallel. 
3.2. Metoprolol MIPs capacity analysis by SPE-HPLC 
An HPLC detection method for metoprolol was developed and a detection limit of 7.5 
ng mL-1 was achieved in the investigation range of 1.5-1000 ng mL-1. Linear regression analysis 
was conducted with average data of three analysis and R2 value was found as 1 with minimal 
standard deviation (<0.05%). After the development of a successful metoprolol detection method 
with HPLC, SPE application was conducted as described above for diclofenac. Residual 
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concentrations of metoprolol in samples collected after SPE analysis could then be determined by 
HPLC and the results are summarized in Table 1 and in Fig.2b. Four metoprolol standards were 
also analyzed to calculate the response and to do comparative data analysis. The concentration of 
the metoprolol starting solution used for the loading was calculated as 257.13 ng mL-1 using the 
HPLC calibration curve. The responses after the pharmaceutical loading on SPE reveals a high 
level uptake of metoprolol by metoprolol MIPNPs immobilized on SPE with 0 ng mL-1 eluted and 
100% uptake. Buffer, cold ACN and hot ACN were loaded on SPE column after metoprolol loading 
to establish the affinity between metoprolol MIP and its target. Metoprolol was not removed from 
the SPE column with either buffer or ACN. The HPLC response indicated zero level for buffer 
loading, cold and hot ACN. 
3.3. Vancomycin MIPs capacity analysis by SPE-HPLC 
An HPLC vancomycin detection method was developed with an investigation range of 
1.5-1000 ng mL-1 and a detection limit of 15 ng mL-1 was obtained. The linear regression analysis 
was carried out with average data of three analysis and R2 value was found as 0.9998 with very 
low standard deviation (<0.08%). Once the standards were analyzed, the SPE loading samples 
were then measured by HPLC and peak area allowed to determine vancomycin concentration. 
Results are reported in Table 1 and Fig.2c. The vancomycin concentration in the starting solution 
was evaluated by HPLC and a value of 164.7 ng mL-1 was obtained. The residual vancomycin in 
the filtrates after loading it on SPE was evaluated by HPLC as 82.25 ng mL-1. This reveals an 
average uptake of vancomycin of 50.1% by vancomycin MIPNPs immobilized on SPE. Buffer, 
cold ACN and hot ACN were loaded on SPE column after vancomycin. A small amount of the 
drug (26.9 ng mL-1) was removed by the buffer, which indicates a lower affinity between 
vancomycin MIPNPs and its target than for the two other drugs. Nevertheless vancomycin was not 
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removed from the SPE column by ACN, as the HPLC response indicated zero level for both cold 
and hot ACN loading. Due to the complex structure and bigger size of vancomycin, its imprinting 
is more difficult than the other two pharmaceuticals and this might have caused a less stabile yield 
with lower monodispersity. Therefore, the uptake of vancomycin by its MIPNP on the SPE column 
was found lower than the other drugs. 
3.4. Plasma treatment on PVDF membranes 
Membranes supplied by GVS Filter Technology (Zola Predosa, Italy) were PVDF 
membranes produced by means of vapour induced phase separation (VIPS) and have pores with 
an average size of 3 µm. The membranes were modified by plasma treatment which is a common 
method used for surface modification. The process consists of plasma exposure to generate free 
radicals and graft hydrophilic monomers. In this case, acrylic acid was used as the monomer during 
the plasma deposition process and a high density of carboxylic groups could be obtained at the 
surface of the membranes. By means of a dye method the amount of grafted carboxylic groups on 
the membrane surface could be quantified [27, 28]. The untreated PVDF membrane contains 
1.44x109 carboxylic groups per square mm of membrane surface, while after plasma treatment; 
the density of carboxylic groups is increased up to 8.93x109 sites per square mm. The presence of 
the carboxylic groups at the surface of the plasma-treated membranes also gives rise to a drastic 
decrease of the water contact angle of the membrane surface: while the water contact angle of the 
untreated membrane is 128°, this value drops to less than 10° after plasma treatment. After 5 
seconds of contact with the plasma treated membrane, the water droplet is completely absorbed. 
These values remain unchanged after immersion of the plasma treated membrane in MilliQ water 
for 200 hours, indicating that the effect of the plasma treatment in stable in water. Thus, it can 
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concluded that the carboxylic groups grafted on the PVDF-membrane are stable in water and are 
ideal anchorage sites for the MIPNPs which possess amine groups. 
3.5. Functionalization of nanostructured polymeric membranes 
One batch of MIP production yielded ~15 mg of MIPNPs in 150 mL of aqueous solution [26, 29-
30]. For each membrane piece (2.4×7 cm), 3 mL of MIP solution was applied and the MIPNP 
immobilized both by adsorption and covalent immobilization. After the incubation time, the MIP 
solutions remained in Petri dishes were collected and measured by UV spectrometer. The level of 
MIP immobilization on the membranes were analyzed and found to be 69%±1.5%, 67%±2% and 
62%±1.8% for diclofenac-, metoprolol- and vancomycin-MIPs, respectively. The standard and 
functionalized membranes were comparatively visualized by employing SEM and a clear 
difference was observed before and after MIP immobilization (Fig.3). After MIP immobilization 
the membranes surface appears to be more roughened, possibly due to etching and acrylic acid 
deposition that take place during the plasma process as well as the presence of MIP nanoparticles 
on the membrane which resulted in a less smooth membrane surface since the MIP surrounded the 
membrane pores.  
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 a) 
 
b) 
 
Fig 3. Scanning electron microscopy images of standard (a) and MIP immobilized (b) 
nanostructured polymeric membranes. 
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3.6. Diclofenac MIM performance analysis 
The capacity of MIMs was evaluated with 4 mL filtration of diclofenac solution (200 ng 
mL-1) using a vacuum system. The HPLC analysis of the filtrates was performed in parallel of the 
SPE analysis, with the same standards. Two membranes were also used as the control, which refers 
to the drug loading on the membrane without MIPNPs. The amount of diclofenac found in the 
filtrates after drug loading was 10.58 ± 0.11 ng mL-1, meaning that the imprinted membrane were 
able to bind 94.7 ± 0.05 % of the pharmaceutical from aqueous solution (Table 2). This 
corresponds up to 45.09 ng cm2. At the same time, the control membranes did not retain the 
pharmaceutical as most of the drug was found in the filtrates. This could be due to the large pore 
size of the membranes as compared with the pharmaceuticals. HPLC responses are summarized in 
Fig.4a.  
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Fig 4. Diclofenac (a), metoprolol (b) and vancomycin (c) concentrations for standards and filtrates 
determined by HPLC after loading on the membranes. Loading sample represents the starting 
solution of each pharmaceutical. 
 
 
 
 
 
 
 
a) b) 
c) 
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Table 2. Pharmaceutical detection by HPLC after membrane filtration. 
 Membrane Application Membrane loading 1 Membrane loading 2 
D
ic
lo
fe
n
a
c
 
Residual concentration in filtrates ng mL-1 38.47 37.94 
Capacity percentage 94.67% uptake 94.75% uptake 
M
e
to
p
ro
lo
l Residual concentration in filtrates ng mL-1 0.97 1.11 
Capacity percentage 99.62% uptake 99.57% uptake 
V
a
n
c
o
m
y
c
in
 
Residual concentration in filtrates ng mL-1 93.08 96.07 
Capacity percentage 43.49% uptake 41.67% uptake 
C
o
n
tr
o
l Residual concentration in filtrates ng mL-1 200  200 
Capacity percentage 0% uptake 0% uptake 
 
3.7. Metoprolol MIM performance analysis 
Metoprolol MIM performance analysis was performed as described before. The 
concentration for metoprolol in the starting solution was 257.13 ng mL-1 and this amount was 
calculated based on the HPLC standards (Fig.4b). The residual amount of metoprolol found in the 
filtrates was 1.04 ± 0.10 ng mL-1, meaning that the imprinted membranes were able to bind 99.59 
± 0.04% of the pharmaceutical from aqueous solution (Table 2). This corresponds to up to 60.39 
ng cm2.  
3.8. Vancomycin MIM performance analysis 
The concentration of vancomycin in the starting solution was 164.7 ng mL-1, which was 
determined using the HPLC standards (Fig.4c). The concentration of vancomycin in the filtrates 
after loading was of 94.58 ± 2.12 ng mL-1, meaning that the imprinted membranes were able to 
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bind 42.6 ± 1.3 % of the pharmaceutical from aqueous solution (Table 2). This corresponds to up 
to 16.8 ng cm2. 
3.9. Comparative study for MIP immobilization on membrane 
Here, we aimed to observe the effect of covalent immobilization of MIPNPs onto 
membranes by applying EDC-NHS coupling chemistry as compared with simple adsorption. For 
the experiment one set of membranes was processed without EDC-NHS treatment prior to MIPNP 
immobilization. Another set of membranes were processed with EDC-NHS chemistry. The 
membranes were used in a filtration system to filter the solutions of the target analytes (200 ng 
mL-1 diclofenac on diclofenac-MIP immobilized membrane, 200 ng mL-1 metoprolol on 
metoprolol-MIP immobilized membrane and 200 ng mL-1 vancomycin on vancomycin-MIP 
immobilized membrane). The same concentration (200 ng mL-1) of each target was used as starting 
solutions, whereas 30 ng mL-1, 60 ng mL-1 and 200 ng mL-1 were used as standards. A small 
percentage (4.89%) of 200 ng mL-1 diclofenac was found in filtrate samples in the case of 
adsorption based MIPNP immobilization, whereas the amount was slightly higher (6.1%) for 
MIPNP immobilized by EDC-NHS chemistry. After loading the drug samples, buffer loading was 
also performed on two sets of membranes to calculate the residual amount of the drug after buffer 
loading which also shows the removal of the drug from the membrane by buffer.. Only 3.9% and 
2.6% release of diclofenac was observed on EDC-NHS treated/untreated diclofenac-MIP 
immobilized membranes, respectively (Fig.5a). However, the HPLC response obtained for these 
filtrates were under the HPLC detection limit of 3.75 ng mL-1.  
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Fig 5. Comparative membrane studies for diclofenac (a), metoprolol (b) and vancomycin (c) 
with/out EDC-NHS chemistry prior to MIP immobilization. (1: HPLC response of pharmaceutical 
in filtrate after filtration on the membrane, 2: Removal of pharmaceutical from the membrane after 
buffer filtration. First three columns of each graph display the HPLC results of three standards for 
each pharmaceuticals. The starting solution of each pharmaceutical sample was also 200 ng mL-1) 
 
The results for metoprolol-MIP immobilized membranes are also summarized in Fig.5b. 
No metoprolol (0% of 200 ng mL-1) was found in any filtrated solutions in all cases. A difference 
between EDC-NHS treated and untreated membranes was not observed as well as there was no 
release of metoprolol from metoprolol-MIPNP immobilized membranes in the case of buffer 
loading. 
The success of membrane application for vancomycin filtration was clearly less than the 
other two targets (Fig.5c). This is due to the low quality and uniformity of vancomycin-MIPNP 
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because of difficulties during the imprinting process. However, the positive effect of EDC-NHS 
application for vancomycin-MIP was obvious in this case. A relative high percentage (14.86% of 
200 ng mL-1) of vancomycin was found in filtrates of vancomycin-MIPNP immobilized membrane 
without EDC-NHS application, whereas the percentage was halved (7.5%) in the case of EDC-
NHS treated membrane. Moreover, due to the higher stability of MIPNP immobilization on the 
membrane with the aid of EDC-NHS, buffer loading on this membrane did not cause high level of 
release (16.59%) from the membrane, as compared to buffer loading on the adsorption membrane 
(47.34%) which was not treated with EDC-NHS. 
Based on the results reported above, we can conclude that there is no effective difference 
between adsorption and covalent immobilization of diclofenac-MIPNP and metoprolol-MIPNP on 
the membrane, whereas there is a clear difference for vancomycin-MIPNP. In our application, the 
filtration time was quite short (~2 seconds) and the volume of filtrated solution was small (~4 mL). 
Another important point is that each membrane was used only for one set of experiment. In the 
case of long time processes with high volume of solution to be filtered, MIPNP immobilization by 
EDC-NHS can be more important. The benefit of EDC-NHS chemistry could be even more 
significant when membranes are reused for many times, since this chemistry can strongly stabilize 
the MIPNPs on the membrane for a long time. The results of vancomycin-MIP immobilized 
membranes have been supporting this idea. To see the efficiency of covalent immobilization with 
much higher volumes and membrane reuse, we also conducted a pilot test in which different 
volumes of water (1 litre, 2 litres and 5 litres) were filtered on the nanostructured polymeric 
membranes. The same membranes were used during all filtration period and the total removal of 
MIPNPs from the membranes was found as 10.01%±2% (n=3) and 19.01%±3.5% (n=3) for 
covalent and adsorption-based immobilization, respectively. The results indicate both a clear 
26 
 
difference between the two immobilization methods and a gradual removal when higher volumes 
of water filtration are used. To decrease the level of MIP removal from the membrane during an 
extensive time period and in the case of high filtration volumes, membrane characteristics and/or 
plasma treatment process can be further improved. 
4. Conclusions 
Pharmaceuticals and their metabolites can reach the aquatic environment and drinking 
waters if they are not eliminated during sewage treatments. Moreover, some compounds used for 
landfills or animals treatment enter directly environmental waters without going through sewage 
treatments. The development of an efficient filtration system has crucial importance to prevent 
toxic effect of the drugs, which may cause health problems. In this work, we successfully 
developed a functionalized nanostructured polymeric membrane with the aid of molecular 
imprinting technology and plasma treatment for the first time. The membranes are capable of 
selective removal of three commonly used pharmaceuticals. MIPNPs capacity analysis by SPE-
HPLC revealed 100%, 96.3%, and 50.1% uptake of loaded solutions of metoprolol, diclofenac and 
vancomycin, respectively. MIMs performance analysis using HPLC achieved 99.6% uptake with 
a capacity of 60.39 ng cm2 for metoprolol; 94.7% uptake with a capacity of 45.09 ng cm2 for 
diclofenac and 42.6% uptake with a capacity of 16.9 ng cm2 for vancomycin. A small scale pilot 
test also indicated the promising future application of the membrane with high volume of filtrates 
in the case of covalent immobilization of the MIPNPs on the plasma-treated PVDF membranes.   
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